AMICAS (AMCS) to Acquire Emageon (EMAG) for $1.82/Share
More News related to AMCS
- Raymond James Upgrades AMICAS (AMCS) to Strong Buy
- AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009
- AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009
- AMICAS PACS For Mammography at RSNA 2009
- AMICAS Inc. (AMCS) Tops Q3 EPS by 4c; Guides Higher for Q4 Revenues
More News related to EMAG
- AMICAS (AMCS) to Acquire Emageon (EMAG) for $1.82/Share
- Notable Mergers and Acquisitions of the Day 2/13: THOR, INFA, EMAG
- Emageon (EMAG) Receives $9M in Escrow Funds from Health Systems Solutions; Terminates Merger Agreement
- Unusual 11 Mid-Day Movers 2/11: TSCC, NFP, XL, CRAY Higher; EMAG, MOD, GXP, LBY Lower
- Unusual 11 Mid-Day Movers 12/30: EMAG, SVNT, IRM, ALY Higher; SIL, APWR, RICK, EVR Lower
More News related to Mergers and Acquisitions
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
AMICAS, Inc. (Nasdaq: AMCS) and Emageon Inc. (Nasdaq: EMAG) announced today that they have entered into a definitive merger agreement for AMICAS to acquire Emageon Inc.
Under the terms of the agreement, a subsidiary of AMICAS will commence a tender offer to acquire all of the outstanding shares of Emageon common stock for $1.82 per share in cash, for a total of approximately $39 million. The board of directors of Emageon has unanimously recommended that shareholders tender their shares in the offer. AMICAS ended 2008 with a cash, cash equivalents, and marketable securities balance of approximately $55 million and no long term debt.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
